Thyrocare Technologies Limited — PPTs, 23-04-2025: Investor Presentation

The latest earnings presentation reveals significant growth for Thyrocare Technologies in FY25, showcasing a consolidated revenue of ₹687 Cr, marking a 20% increase year-on-year. The pathology revenue surged by 23%, with a standout performance in franchise revenue, which grew by 22%, and partnerships (excluding API) soaring by 40%. Operationally, the company processed 167.9 million tests and served 16.7 million patients, reflecting an 11% increase in patient volume. The EBITDA is also impressive, with normalized EBITDA rising by 78%, underscoring efficient cost management and increased operational leverage.

Strategically, Thyrocare is focused on expanding its footprint through acquisitions, including Polo Labs and Vimta Clinical Diagnostics, enhancing its presence in North and Southern India. The company is also bolstering its home healthcare services with ECG at Home, covering 1,150 pincodes. Looking ahead, the firm aims to deepen its market presence, optimize its franchise network, and strengthen partnerships, ensuring a positive outlook for continued growth and business development. Investors should watch closely for how these initiatives unfold.